Streetbeat News

TIVC

Tivic Health Systems, Inc.

https://www.tivichealth.com

Industry

Medical - Devices

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Open

0.30

Mkt cap

1.8M

Volume

2.2M

High

0.31

P/E Ratio

0.02

52-wk high

3.21

Low

0.25

Div yield

N/A

52-wk low

0.22

Tivic Health has partnered with Fletcher Spaght to enhance its commercial strategy for non-invasive cervical vagus nerve stimulation. The global market for vagus nerve stimulation is expected to grow significantly, with Tivic Health targeting a rapidly expanding segment.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 1:07 pm

Tivic Health Systems (NASDAQ:TIVC) reported Q2 EPS of $(0.32), a significant improvement from $(7.16) YoY. However, sales decreased by 13.04% to $140.00K from $161.00K YoY.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:32 pm

Shares of Advanced Micro Devices, Inc. (AMD) surged over 9% in pre-market trading after reporting better-than-expected Q2 earnings and sales. Several other stocks also saw significant pre-market movements, including Primech Holdings Ltd. (PMEC), Heramba Electric plc (PITA), and NuZee, Inc. (NUZE) among gainers, and FibroGen, Inc. (FGEN) and MacroGenics, Inc. (MGNX) among losers.

Portfolio Pulse from Avi Kapoor

July 31, 2024 | 9:46 am

Bank of Marin Bancorp (NASDAQ:BMRC) shares fell sharply after reporting worse-than-expected quarterly earnings. Other notable stock movements include 2U, Inc. (NASDAQ:TWOU) climbing 128% and Cognition Therapeutics, Inc. (NASDAQ:CGTX) falling 34%.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 5:19 pm

Pitney Bowes shares surged over 12% in pre-market trading after selling part of its e-commerce business to Stord. Other notable pre-market movers include Cognition Therapeutics, Longeveron, and Abbott Laboratories, among others.

Portfolio Pulse from Avi Kapoor

July 29, 2024 | 9:26 am

Tivic Health Systems, Inc. (NASDAQ:TIVC) shares surged 34.8% to 41 cents on Thursday, driven by heavy trading volume and the announcement of three new patents in the U.S. and Europe. The company focuses on non-invasive bioelectronic medicine, including its ClearUP Sinus Relief device.

Portfolio Pulse from Erica Kollmann

July 25, 2024 | 8:16 pm

Edwards Lifesciences Corporation (NYSE:EW) shares fell sharply after reporting worse-than-expected Q2 sales and issuing weak Q3 guidance. Despite beating EPS estimates, the stock dipped 26.9%. The company also acquired JenaValve and Endotronix. Other notable movers include Predictive Oncology Inc. (NASDAQ:POAI), Psyence Biomedical Ltd. (NASDAQ:PBM), and Ford Motor Company (NYSE:F).

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 6:12 pm

Indivior PLC (NASDAQ:INDV) shares surged 14.5% in pre-market trading after reporting better-than-expected Q2 earnings and announcing a $100 million share repurchase program. Other notable pre-market movers include Psyence Biomedical Ltd. (NASDAQ:PBM), BloomZ Inc. (NASDAQ:BLMZ), and 2U, Inc. (NASDAQ:TWOU), among others.

Portfolio Pulse from Avi Kapoor

July 25, 2024 | 10:36 am

Tivic Health Systems has received three new patents from the USPTO and EPO, advancing its bioelectronic medicine technology. The patents cover adaptive triggers for microcurrent stimulation devices and dynamic voltage adjustments for sinus treatment devices, enhancing device performance and user experience.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 2:01 pm

The article reports on the after-market movements of 12 health care stocks on Thursday. Notable gainers include OneMedNet, 23andMe Holding, and Biora Therapeutics, while significant losers include Genelux and Evoke Pharma.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.